CF

Climate-Smart Commodities Program to Benefit 180,000 Farms, Agritech Leads the Way

Retrieved on: 
Thursday, May 9, 2024
Administration, Investment, News, Research, Market, Partnership, Farmer, Usenet newsgroup, Farm, Ammonia, Food, ACN, Soil, CF Industries, Plant, Soybean, Sustainability, TSX, Fertilizer, BVT, PGPR, Strait, Rapeseed, Nutrien, Michigan State University, National FFA Organization, Health, The Mosaic Company, USDA, Fungal infection, Crop protection, JDA, Sale, Agriculture, Interview, CropLife International, JERA, NTR, Environment, Inflation, Growth

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In order to help farmers advance conservation and climate-smart agriculture, the USDA recently made $1.5 billion available as part of US President Biden's Investing in America Agenda. The newly-available capital is part of several climate-smart agriculture investments the USDA has made since the beginning of the current Administration's reign, which have been made through the Inflation Reduction Act, and the Partnerships for Climate-Smart Commodities program, which have been estimated to support over 180,000 farms and over 225 million acres in the next 5 years. According to analysts at Straits Research the Smart Agriculture Market is projected to reach US$36.24 billion by 2030, growing at a CAGR of 10.8%, while Markets and Markets predicts the Precision Farming Market to grow to US$21.9 billion by 2031, growing at a CAGR of 10.7%. As farmers and the agriculture industry works to produce environmentally friendly food that meets these goals, several agritech companies are working behind the scenes to help, including Bee Vectoring Technologies International Inc. (CSE: BEE) (OTCQB: BEVVF), Nutrien Ltd. (NYSE: NTR) (TSX: NTR), The Mosaic Company (NYSE: MOS), CF Industries Holdings, Inc. (NYSE: CF), and Bunge Global SA (NYSE: BG).

Key Points: 
  • BVT recently updated its corporate partnership strategy , securing new international trials and expanding the use of its flagship asset, CR-7.
  • "This trial demonstrates that CR-7 could be integrated into a pre-bloom or post-bloom spray program to extend disease control throughout the season."
  • We are thrilled to harness his expertise as we continue to revolutionize the way crops are cultivated and protected."
  • "Food, feed & fuel customers will benefit from a broader product portfolio and expanded global supply options."

Climate-Smart Commodities Program to Benefit 180,000 Farms, Agritech Leads the Way

Retrieved on: 
Thursday, May 9, 2024
Administration, Investment, News, Research, Market, Partnership, Farmer, Usenet newsgroup, Farm, Ammonia, Food, ACN, Soil, CF Industries, Plant, Soybean, Sustainability, TSX, Fertilizer, BVT, PGPR, Strait, Rapeseed, Nutrien, Michigan State University, National FFA Organization, Health, The Mosaic Company, USDA, Fungal infection, Crop protection, JDA, Sale, Agriculture, Interview, CropLife International, JERA, NTR, Environment, Inflation, Growth

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In order to help farmers advance conservation and climate-smart agriculture, the USDA recently made $1.5 billion available as part of US President Biden's Investing in America Agenda. The newly-available capital is part of several climate-smart agriculture investments the USDA has made since the beginning of the current Administration's reign, which have been made through the Inflation Reduction Act, and the Partnerships for Climate-Smart Commodities program, which have been estimated to support over 180,000 farms and over 225 million acres in the next 5 years. According to analysts at Straits Research the Smart Agriculture Market is projected to reach US$36.24 billion by 2030, growing at a CAGR of 10.8%, while Markets and Markets predicts the Precision Farming Market to grow to US$21.9 billion by 2031, growing at a CAGR of 10.7%. As farmers and the agriculture industry works to produce environmentally friendly food that meets these goals, several agritech companies are working behind the scenes to help, including Bee Vectoring Technologies International Inc. (CSE: BEE) (OTCQB: BEVVF), Nutrien Ltd. (NYSE: NTR) (TSX: NTR), The Mosaic Company (NYSE: MOS), CF Industries Holdings, Inc. (NYSE: CF), and Bunge Global SA (NYSE: BG).

Key Points: 
  • BVT recently updated its corporate partnership strategy , securing new international trials and expanding the use of its flagship asset, CR-7.
  • "This trial demonstrates that CR-7 could be integrated into a pre-bloom or post-bloom spray program to extend disease control throughout the season."
  • We are thrilled to harness his expertise as we continue to revolutionize the way crops are cultivated and protected."
  • "Food, feed & fuel customers will benefit from a broader product portfolio and expanded global supply options."

Royalty Pharma Reports First Quarter 2024 Results

Retrieved on: 
Thursday, May 9, 2024
FDA, Ulcerative colitis, KarXT, Food, MorphoSys, European Commission, Marketing, New Drug Application, Cystic fibrosis, PDSS, PANSS, Tourette syndrome, Lupus, Docetaxel, Roche, Schizophrenia, Novartis, ADP, Pfizer, Incidence, Bristol Myers Squibb, Patient, Neurology, Acquisition, Sacituzumab govitecan, Olanzapine, Civil service commission, Multiple sclerosis, Positive, Vertex, Sanofi, Teva Pharmaceuticals, Astellas Pharma, European Medicines Agency, Lung cancer, Pharmaceutical industry

During 2024, Royalty Pharma announced new transactions of up to $619 million.

Key Points: 
  • During 2024, Royalty Pharma announced new transactions of up to $619 million.
  • In January 2024, Royalty Pharma acquired a royalty interest in ecopipam for an upfront payment of $49 million and up to $44 million in milestone payments contingent on the achievement of certain regulatory milestones.
  • In May 2024, Royalty Pharma announced a transaction to acquire royalties and milestones on frexalimab owned by ImmuNext for approximately $525 million in cash including estimated transaction costs.
  • Royalty Pharma has provided guidance for full year 2024, excluding transactions and borrowings announced after the date of this release, as follows:

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

Retrieved on: 
Thursday, May 9, 2024
FDA, Regenerative medicine, Research, Choroideremia, Biopsy, European Medicines Agency, Injection, Overalls, Inflammation, Food, Alpha-1 antitrypsin, Cystic fibrosis, Chelsea Handler, Intravitreal administration, Conference, Retina, Atypical hemolytic uremic syndrome, DME, Angiogenesis, PRISM, AMD, Safety, Security (finance), Cash, Retinitis pigmentosa, Exercise, PRIME, EMA, NHP, Clinical trial, A1AT, ASRS, ARVO, ECFS, Șaeș, Cubic foot, Patient, Society, Geographic atrophy, Pharmaceutical industry

“The first quarter of 2024 kicks off another transformative year for 4DMT with exceptional progress across our product pipeline and platform in multiple therapeutic areas, particularly our lead program 4D-150 in large market VEGF-driven retinal diseases,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.

Key Points: 
  • “The first quarter of 2024 kicks off another transformative year for 4DMT with exceptional progress across our product pipeline and platform in multiple therapeutic areas, particularly our lead program 4D-150 in large market VEGF-driven retinal diseases,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
  • R&D Expenses: Research and development expenses were $27.9 million for the first quarter of 2024, as compared to $22.4 million for the first quarter of 2023.
  • G&A Expenses: General and administrative expenses were $10.3 million for the first quarter of 2024, as compared to $8.0 million for the first quarter of 2023.
  • Net Loss: Net loss was $32.4 million for the first quarter of 2024, as compared to net loss of $28.7 million for the first quarter of 2023.

Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
Monday, May 6, 2024
Momentum, FDA, Ophthalmology, Interleukin, Investment, Research, DEB, Orphan, Trial of the century, Form, NCT, PI, ODD, GAAP, AATD, European Medicines Agency, Food, Transgene, Medicaid, Medicine, Eye, Patent, Certification, KRYS, EMA, Lung, GMP, Jeune, MAA, Administration, Rest, Patient, Genotype, Annual general meeting, Growth, Pharmaceutical industry

PITTSBURGH, May 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the first quarter ending March 31, 2024.

Key Points: 
  • PITTSBURGH, May 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the first quarter ending March 31, 2024.
  • Patient compliance with once weekly treatment while on drug remains high at 91% as of the end of the quarter.
  • Financial Results for the Quarter Ended March 31, 2024:
    Cash, cash equivalents, and investments totaled $622.3 million on March 31, 2024.
  • For additional information on the Company’s financial results for the quarter ended March 31, 2024, please refer to the Form 10-Q filed with the SEC.

CF Industries Holdings, Inc. to Participate in Upcoming Investor Conference

Retrieved on: 
Tuesday, May 7, 2024
Other Energy, Oil, Gas, Sustainability, Environment, Alternative Energy, Energy, Chemicals, Plastics, Manufacturing, CF Industries, Conference, Webcast

CF Industries Holdings, Inc. (NYSE: CF) today announced that the Company will present at the BMO Global Farm to Market Conference at 8:45 am ET on Wednesday, May 15, 2024.

Key Points: 
  • CF Industries Holdings, Inc. (NYSE: CF) today announced that the Company will present at the BMO Global Farm to Market Conference at 8:45 am ET on Wednesday, May 15, 2024.
  • Investors who wish to access the live conference webcast should visit the Investor Relations section of the company’s website at www.cfindustries.com .
  • A replay of the webcast will be available on the CF Industries Holdings, Inc. website for 180 days following the events.

Carbon Biosciences Announces Four Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

Retrieved on: 
Thursday, May 2, 2024
Carbon, Parvoviridae, Analytic, Tropism, Poster, Heart, Cystic fibrosis, CFTR, Primate, Cell, Abstract, AAV, PAVE, Liver, Patient, Gene, Process, Society, Lung, Annual general meeting, Capsid, CBN, Knowledge, Vaccine

WALTHAM, Mass., May 2, 2024 /PRNewswire/ -- Carbon Biosciences, a preclinical stage biotechnology company developing genetic medicines for the treatment of pulmonary and cardiac diseases, announced that it has been selected for an oral presentation at the Presidential Symposium during the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place from May 7-11, 2024, in Baltimore, MD. The presentation will highlight the development of CGT-001, a potential gene therapy for the treatment of Cystic Fibrosis (CF), which utilizes the novel pulmonary targeting vector, CBN-1000, capable of delivering genes beyond the capacity of AAV. In addition, the Company will be featuring three poster presentations detailing new preclinical data, and manufacturing process development and analytical characterization for two of its novel viral gene therapy vectors.

Key Points: 
  • In addition, the Company will be featuring three poster presentations detailing new preclinical data, and manufacturing process development and analytical characterization for two of its novel viral gene therapy vectors.
  • Key insights from Carbon Biosciences' presentations at ASGCT:
    CBN-1000, a non-AAV parvovirus-based gene therapy vector, demonstrates excellent tolerability and transgene expression throughout the lung and airway in nonhuman primates after nebulization.
  • CBN-1100 vector demonstrates transgene packaging of up to 5.9 kb, representing >1 kb more capacity than AAV vectors.
  • The complete absence of expression in the liver suggests the potential for a differentiated specificity and safety profile compared to AAV-based vectors for cardiac gene therapy.

Canton Fair and Guangzhou Branch of the National Archives of Publications and Culture Forge Deep Collaboration with Design Innovation Award

Retrieved on: 
Monday, April 29, 2024
MOU, Fair, SME, Statistics, AI, Partnership, Speech, Canton Fair, National archives, Culture, Film industry

GUANGZHOU, China, April 28, 2024 /PRNewswire/ -- During the second phase of the 135th China Import and Export Fair ("Canton Fair" or "the Fair"), a significant memorandum of cooperation was signed between the Fair and the Guangzhou Branch of the National Archives of Publications and Culture, marking a milestone in recognizing the industrial innovation of Canton Fair Design Award (CF Award) winners through design.

Key Points: 
  • GUANGZHOU, China, April 28, 2024 /PRNewswire/ -- During the second phase of the 135th China Import and Export Fair ("Canton Fair" or "the Fair"), a significant memorandum of cooperation was signed between the Fair and the Guangzhou Branch of the National Archives of Publications and Culture, marking a milestone in recognizing the industrial innovation of Canton Fair Design Award (CF Award) winners through design.
  • This partnership will see top selected CF Award-winning products archived at the national museum, showcasing the vibrant development across industries.
  • Zhang Weitao, Deputy Director of National Archives of Publications and Culture, emphasized during his speech that these award-winning products represent the strength of industrial innovation in this new era.
  • Participants provided thorough insights into how productive service design, technological innovations, industrial upgrading strategies, and AI advancements could redefine productivity standards.

Canton Fair and Guangzhou Branch of the National Archives of Publications and Culture Forge Deep Collaboration with Design Innovation Award

Retrieved on: 
Sunday, April 28, 2024
MOU, Fair, SME, Statistics, AI, Partnership, Speech, Canton Fair, Multimedia, National archives, Culture, Film industry

GUANGZHOU, China, April 28, 2024 /PRNewswire/ -- During the second phase of the 135th China Import and Export Fair ("Canton Fair" or "the Fair"), a significant memorandum of cooperation was signed between the Fair and the Guangzhou Branch of the National Archives of Publications and Culture, marking a milestone in recognizing the industrial innovation of Canton Fair Design Award (CF Award) winners through design.

Key Points: 
  • GUANGZHOU, China, April 28, 2024 /PRNewswire/ -- During the second phase of the 135th China Import and Export Fair ("Canton Fair" or "the Fair"), a significant memorandum of cooperation was signed between the Fair and the Guangzhou Branch of the National Archives of Publications and Culture, marking a milestone in recognizing the industrial innovation of Canton Fair Design Award (CF Award) winners through design.
  • This partnership will see top selected CF Award-winning products archived at the national museum, showcasing the vibrant development across industries.
  • Zhang Weitao, Deputy Director of National Archives of Publications and Culture, emphasized during his speech that these award-winning products represent the strength of industrial innovation in this new era.
  • Participants provided thorough insights into how productive service design, technological innovations, industrial upgrading strategies, and AI advancements could redefine productivity standards.

Novotech Publishes Analyst Report on Cystic Fibrosis Clinical Trial Landscape to Inform Biotech Research Planning 

Retrieved on: 
Thursday, April 11, 2024
Contract research organization, Mutation, Epithelium, Pancreas, Investment, SWOT, Cystic fibrosis, CFTR, USFDA, Growth, Therapy, Patient, Research report, Medicine, ROW, Life expectancy, Standard of care, Clinical trial, Quality of life, Longevity, Prevalence, Pharmaceutical industry

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) --  Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released a comprehensive research report entitled Cystic Fibrosis - Global Clinical Trial Landscape.

Key Points: 
  • BOSTON, April 10, 2024 (GLOBE NEWSWIRE) --  Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released a comprehensive research report entitled Cystic Fibrosis - Global Clinical Trial Landscape.
  • The report presents a data-backed review of the Cystic Fibrosis (CF) funding landscape, trial density and patient recruitment data across geographies, standard of care and emerging therapies, recent USFDA approvals, and regulatory trends.
  • Importantly it also includes an in-depth SWOT analysis, to guide biotech firms on strategic decision-making, and research opportunities, and challenges.
  • The Novotech research analyst team provides these expert reports on a monthly basis, completely free of charge.